is this you? Claim your profile.
is this you? Claim your profile.
HQ Phone:  (301) 251-1500
Direct Phone: (301) ***-****
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
1650 Research Blvd.
Westat is an employee-owned corporation providing research services to agencies of the U.S. Government, as well as businesses, foundations, and state and local governments. In addition to capabilities as a leading statistical survey research organization, West... more.
Westat | Clinical Trials |2010 News, Awards, Presentations
06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010. Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs. Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them. Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.
PROGRAM - Tuesday, May 18, 2010
Panelists: Winston Wong PharmD, Associate Vice President, Pharmacy Management, CareFirst BlueCross BlueShield, Baltimore, MD, USA; Don P. Buesching PhD, US Outcomes Research Fellow, Eli Lilly and Company, Indianapolis, IN, USA; Jonathan Ratner PhD, Senior Economist, Westat, Rockville, MD, USA
Robert S. Goldfarb and Jonathan Ratner
Jonathan Ratner is a senior economist at Westat, an employee-owned research firm in Rockville, Maryland. Previously, he was an Assistant Director at the Government Accountability Office (GAO), a congressional agency, and an assistant professor at Wellesley College and the State University of New York at Albany. He also served on detail from GAO as a staff member for the U.S. Senate Finance Committee. His academic publications address topics in health economics, macroeconomics, defense economics, and forecasting. He is the author or co-author of numerous GAO reports on health economics and policy. He has testified at congressional hearings and appeared on NBC Nightly News. His email is email@example.com.
"Theory" and "Models": Terminology Through the Looking Glass · Econ Journal Watch : models, model building, theory, explanation, explanandum, story telling, relevance, importance
by Robert S. Goldfarb and Jon Ratner
*Jonathan Ratner* is a senior economist at Westat, an employee-owned research firm in Rockville, Maryland. Previously, he was an Assistant Director at the Government Accountability Office (GAO), a congressional agency, and an assistant professor at Welles
Westat - News Archives 2010
Gad Nathan, Ph.D. (2001)
Jonathan Ratner and Andrew Giffin.